Physician profile
Steven Shepherd
NPI 1225018534
$2,492.88
in general payments reported to CMS, 2019-2025
24 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $160 · 2021: $13.14 · 2022: $153 · 2023: $371 · 2024: $828 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.61 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $424.63 | 2019-2025 | Repatha, Evenity, Repatha |
| Novo Nordisk INC | $330.07 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $239.89 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $177.29 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $161.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $157.21 | 2019-2025 | Airsupra, Breztri |
| Coloplast Corp | $132.50 | 2019 | |
| Lilly USA, LLC | $125.20 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $121.05 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $108.67 | 2023-2025 | Nexletol |
| Alk-Abello, INC | $91.46 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.60 | 2019-2024 | |
| Amarin Pharma, INC. | $77.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $75.13 | 2022-2023 | |
| Abbvie INC. | $35.02 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $24.89 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.66 | 2024 | Xifaxan |
| Abbott Laboratories | $19.61 | 2023 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $16.28 | 2025 | Opsumit, Uptravi |
| Horizon Therapeutics Plc | $14.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.64 | 2025 | Voquezna |
| Dermira, INC. | $14.45 | 2020 | |
| Ibsa Pharma INC. | $13.46 | 2024 | Tirosint, Licart |
| Alydia Health | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.